{
    "organizations": [],
    "uuid": "e404b3b3ac98efdd922ea73340a1625c6889c2e7",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-deciphera-pharma-expects-to-start/brief-deciphera-pharma-expects-to-start-late-stage-study-in-patients-with-gastric-tract-tumors-in-second-half-of-2018-idUSFWN1RU0YQ",
    "ord_in_thread": 0,
    "title": "BRIEF-Deciphera Pharma Expects To Start Late-Stage Study In Patients With Gastric Tract Tumors In Second Half Of 2018",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 17 (Reuters) - Deciphera Pharmaceuticals Inc:\n* PRECLINICAL DATA DEMONSTRATE THAT DECIPHERA PHARMACEUTICALS’ DCC-2618 EXHIBITS BROADER INHIBITION PROFILE AGAINST PRIMARY AND SECONDARY DRUG-RESISTANT MUTATIONS IN GASTROINTESTINAL STROMAL TUMORS (GIST) COMPARED TO APPROVED AND INVESTIGATIONAL AGENTS\n* DECIPHERA PHARMACEUTICALS - DCC-2618 DEMONSTRATED BROADEST PROFILE OF INHIBITION OF PRIMARY AND SECONDARY KIT MUTATIONS AND PRIMARY PDGFRΑ MUTATIONS\n* DECIPHERA PHARMACEUTICALS INC - EXPECTS TO INITIATE A PHASE 3 REGISTRATION STUDY IN 2(ND) LINE GIST PATIENTS IN SECOND HALF OF 2018\n* DECIPHERA PHARMACEUTICALS INC - EXPECTS TO REPORT TOP-LINE DATA FROM ONGOING INVICTUS STUDY IN 2019 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-17T21:18:00.000+03:00",
    "crawled": "2018-04-18T17:58:28.012+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "deciphera",
        "pharmaceutical",
        "inc",
        "preclinical",
        "data",
        "demonstrate",
        "deciphera",
        "pharmaceutical",
        "exhibit",
        "broader",
        "inhibition",
        "profile",
        "primary",
        "secondary",
        "mutation",
        "gastrointestinal",
        "stromal",
        "tumor",
        "gist",
        "compared",
        "approved",
        "investigational",
        "agent",
        "deciphera",
        "pharmaceutical",
        "demonstrated",
        "broadest",
        "profile",
        "inhibition",
        "primary",
        "secondary",
        "kit",
        "mutation",
        "primary",
        "pdgfrα",
        "mutation",
        "deciphera",
        "pharmaceutical",
        "inc",
        "expects",
        "initiate",
        "phase",
        "registration",
        "study",
        "nd",
        "line",
        "gist",
        "patient",
        "second",
        "half",
        "deciphera",
        "pharmaceutical",
        "inc",
        "expects",
        "report",
        "data",
        "ongoing",
        "invictus",
        "study",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}